Product Launch Tracker: eHCPs celebrate approval in cervical cancer

01.02.2024 | Tracker

Product Launch Tracker: eHCPs celebrate approval in cervical cancer

Every month, CREATION.co’s tracking updates bring you the latest insights from the online conversation of healthcare professionals (eHCPs) across the globe discussing product launches. Discover which new drug approvals eHCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout January 2024 CREATION.co tracked the global conversations of 1,255 eHCPs who posted 1,745 English-language X (formerly Twitter) posts about the launches and approvals of new products.

In January, 573 fewer eHCPs discussed treatment approvals compared to December and there were 35% fewer mentions of new pharmaceutical product launches and drug approvals. However, two stories received eHCPs’ attention.

On 12 January, the FDA approved Merck’s Keutruda (pembrolizumab) in combination with chemoradiotherapy, for patients with late-stage cervical cancer. eHCPs expressed optimism regarding the approval, citing the significance of the 18-year gap since the last approval for the combination of pembrolizumab and chemotherapy as a treatment option. A small number of eHCPs characterised the results of this trial assessing this treatment as practice-changing and establishing a new standard of care in cervical cancer treatment.

On 17 January, the FDA approved the first generic of Dificid (fidaxomicin), an antibiotic used to treat an infection called Clostridioides difficile – associated diarrhoea. eHCPs responded with great enthusiasm upon receiving the news of the treatment approval. Some saw the approval as the start of an important year in infectious diseases. Their conviction derived from the perceived simplification of medication access following this FDA approval

The two most shared stories from eHCPs discussing product launches in January were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • Using CREATION Pinpoint® the English-language X conversations of eHCPs globally discussing new pharmaceutical product launches and drug approvals between 1 January and 31 January 2024 were analysed in order to discover which new product launches eHCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by eHCPs in their X conversations.
  • Between 1 January and 31 January 2024, there were 2,732 eHCP mentions of new pharmaceutical product launches and drug approvals from 1,854 unique eHCP authors from around the world. 

 

Share this article

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next


A CREATION Press Release

01.04.2013 | Press Release

Study Reveals Breast Cancer is Most Talked-About Cancer by UK Doctors in Public Social Media

Study Reveals Breast Cancer is Most Talked-About Cancer by UK Doctors in Public Social Media

11.08.2023 | Article

Top 50 Pharma Tracker: eHCP concern about drug shortages after tornado damages Pfizer facility

Discover what healthcare professionals (HCPs) think about pharmaceutical companies

By Aman Jandu

View all articles >